Hays, Inc.

Medtech

SABOT, a catheter for selective aortic balloon occlusion with adjustable partial reperfusion capability for hemorrhage control

haysinnovations.com →
Grants
$1.1M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
4 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Defense · Phase I · Selective Aortic Arch Perfusion Technologies for Hemorrhage-induced Cardiac Arrest$150,000
Federal grantDepartment of Defense · Phase II · Selective Aortic Arch Perfusion Technologies for Hemorrhage-induced Cardiac Arrest$999,234
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2124YELLOWSTONE SCIENTIFIC INSTRUMENTS——
2125DELTAMED LLC——
2126CERETYPE NEUROMEDICINE IN——
2127Hays, Inc.——
2128GENASSIST INC——
2129PREHAB TECHNOLOGIES, LLC——
2130Cardiovate Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 8

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.